Nevro Corp.

NVRO

US64157F1030

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 11:21:11 2024-05-13 am EDT			5-day change	1st Jan Change
10.34 ^USD	+5.62%		-6.77%	-51.70%

May. 08	Truist Securities Lowers Nevro's Price Target to $11 From $14, Hold Rating Maintained	MT
May. 08	Piper Sandler Adjusts Nevro's Price Target to $12 From $15, Maintains Underweight Rating	MT

Nevro Corp. Announces Vale Will Not Stand for Reelection When His Current Term Expires on the Date of the Annual Meeting

April 11, 2022 at 04:48 pm EDT

Nevro Corp. announced that Dr. Vale will not stand for reelection when his current term expires on the date of the Annual Meeting.

Latest news about Nevro Corp.

Truist Securities Lowers Nevro's Price Target to $11 From $14, Hold Rating Maintained	May. 08	MT
Piper Sandler Adjusts Nevro's Price Target to $12 From $15, Maintains Underweight Rating	May. 08	MT
Wells Fargo Trims Nevro Price Target to $13 From $14, Maintains Equal Weight Rating	May. 08	MT
Nevro Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Transcript : Nevro Corp., Q1 2024 Earnings Call, May 07, 2024	May. 07
Earnings Flash (NVRO) NEVRO Reports Q1 Revenue $87M, vs. Street Est of $97.9M	May. 07	MT
Nevro Corp. Provides Earnings Guidance for the Second Quarter Ending June 30, 2024 and Revises Earnings Guidance for the Full Year Ending December 31, 2024	May. 07	CI
Nevro Corp. Announces Resignation of Richard B. Carter as Chief Accounting Officer and Principal Accounting Officer, Effective May 10, 2024	Apr. 25	CI
RBC Lowers Price Target on Nevro to $16 From $18, Keeps Sector Perform Rating	Apr. 15	MT
Mizuho Adjusts Price Target on Nevro to $16 From $20, Maintains Neutral Rating	Apr. 11	MT
Citigroup Cuts Price Target on Nevro to $16 From $18, Maintains Neutral Rating	Apr. 03	MT
Nevro 2024 Sales Expected Slightly Below Estimates, RBC Says	Feb. 22	MT
Wells Fargo Adjusts Price Target on Nevro to $17 From $20, Maintains Equal-Weight Rating	Feb. 22	MT
Baird Cuts Price Target on Nevro to $19 From $23, Maintains Neutral Rating	Feb. 22	MT
Oppenheimer Downgrades Nevro to Perform From Outperform, Removes $35 Price Target	Feb. 22	MT
RBC Lowers Price Target on Nevro to $18 From $20, Keeps Sector Perform Rating	Feb. 22	MT
Earnings Flash (NVRO) NEVRO Posts Q4 Revenue $116.2M, vs. Street Est of $116M	Feb. 21	MT
Engaged Capital Enters into Agreement with Nevro Corp	Feb. 21	CI
Transcript : Nevro Corp., Q4 2023 Earnings Call, Feb 21, 2024	Feb. 21
Nevro Corp. Appoints Kirt P. Karros to Board of Directors and Audit Committee of the Board	Feb. 21	CI
Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2024	Feb. 21	CI
Nevro Corp. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 21	CI
RBC Downgrades Nevro to Sector Perform From Outperform, Cuts Price Target to $20 From $23	Jan. 12	MT
Transcript : Nevro Corp. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 08:15 AM	Jan. 11
Sector Update: Health Care Stocks Mixed in Afternoon Trading	Jan. 09	MT

Nevro Corp. is a global medical device company. The Company is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. It has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-14 - BofA Securities Health Care Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Nevro Corp.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

9.79 USD

Average target price

15.1 USD

Spread / Average Target

+54.24%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
NEVRO CORP.	-51.70%	360M
ABBOTT LABORATORIES	-4.61%	182B
MEDTRONIC PLC	+1.68%	110B
BECTON, DICKINSON AND COMPANY	-2.52%	68.11B
DEXCOM, INC.	+0.75%	50.53B
CENCORA, INC.	+9.52%	44.8B
HOYA CORPORATION	+2.84%	40.7B
METTLER-TOLEDO INTERNATIONAL, INC.	+22.23%	32.25B
WEST PHARMACEUTICAL SERVICES, INC.	+2.88%	26.53B
TERUMO CORPORATION	+15.25%	25.02B

Other Medical Equipment, Supplies & Distribution

Nevro Corp.

Equities

NVRO

US64157F1030

Medical Equipment, Supplies & Distribution

Nevro Corp. Announces Vale Will Not Stand for Reelection When His Current Term Expires on the Date of the Annual Meeting

Latest news about Nevro Corp.

Chart Nevro Corp.

Company Profile

Income Statement Evolution

Ratings for Nevro Corp.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Medical Equipment, Supplies & Distribution